ETX.L Share News (ETX)

LONDON (Dow Jones)--Drug discovery company e-Therapeutics PLC (ETX.LN) Tuesday reported a wider fiscal-year loss and said it remains in talks with drug makers about commercial collaborations. E-Therapeutics, which uses computer software to develop new drugs, added the first of several planned Phase II human trials of its products is scheduled to start in 2011. E-Therapeutics reported a net loss of GBP1.78 million for the year to Jan. 31, compared with a loss of GBP1.55 million a year earlier. Revenue was nil, compared with revenue of GBP67,000 a year earlier. The company cut its administrative expenses but research costs rose. It finished the year with GBP2.88 million in cash. -By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com (END) Dow Jones Newswires June 29, 2010 03:01 ET (07:01 GMT)